John Suzuki

John K. Suzuki has successfully consulted for many top medical devices, biotechnology, and pharmaceutical companies in various scientific and technical roles.

LOS ANGELES (PRWEB)
November 18, 2019

“Evaluation of the Biofield Energy Treated Novel Test Formulation on Overall Organs Health Specific Biomarkers” by John K. Suzuki has been named No. 1 International Best Seller on Amazon in many categories including Holistic Medicine, Mind-Body Connection, Internal Medicine, Reference, Pathology, Science and Math. It was also a No. 1 Hot New Release in Holistic Medicine.

The aim of Suzuki’s research was to study the impact of a Biofield Energy Treated supplement formulation on the function of vital organs including; bones, heart, liver, lungs, and the brain in various cell-based assays.

About Biofield Energy Treatments

The National Center of Complementary and Integrative Health (NCCIH) has recognized and accepted Biofield Energy Healing Treatments as a complementary and alternative medicine (CAM) health care approach in addition to other therapies, medicines, and practices. CAM therapies have been practiced worldwide with reported clinical benefits in different health disease profiles. Human Biofield Energy has subtle energy that has the capacity to work in an effective manner. This energy can be harnessed and transmitted by the gifted into living and non-living things via the process of a Biofield Energy Healing Treatment or Therapy.

About John Suzuki

John K. Suzuki has successfully consulted for many top medical devices, biotechnology, and pharmaceutical companies in various scientific and technical roles. Due to his own health challenges, Suzuki became aware that higher consciousness can have a more profound effect on healing the human body than conventional allopathic medicine. His search to elevate his consciousness led him to Guruji Mahendra Kumar Trivedi and the Trivedi Effect® in 2010. After receiving Guruji Trivedi’s remote energy transmissions, Suzuki’s life transformed on all levels including enhanced physical health. Through Suzuki’s association with Guruji Trivedi, he discovered and developed his own natural ability to harness and transmit healing energy know as Biofield Energy Treatments. His holistic healing power has been validated by scientific research using international cell-based and animal models. The results that have been published in peer-reviewed scientific journals suggest that Suzuki’s Biofield Energy Treatments can improve human health and the quality of life.

http://www.johnksuzuki.com

About the Trivedi Effect® & Guruji Mahendra Trivedi

The Trivedi Effect® is an evidence-based phenomenon in which an individual can harness inherently intelligent energy from nature and transmit it to living organisms and non-living materials, anywhere in the world through thought intention, to significantly enhance potency and beneficially alter their characteristics and behaviors through transformation at the atomic, molecular, and cellular levels.

Guruji Mahendra Kumar Trivedi, Founder of the Trivedi Effect®, is on a mission to usher in a new era that integrates science, spirituality, and consciousness to vastly improve the human condition and benefit humanity on a global scale. To date, more than 250,000 people worldwide have benefited from the Trivedi Effect®. His organization, Trivedi Global, Inc., is collaborating with globally renowned product research and development organizations to bring to market proprietary products and therapies in the areas of nutraceuticals, pharmaceuticals, and more.

Alice Branton, CEO of Trivedi Global, Inc., has spoken on the impact of the Trivedi Effect® at the Entrepreneurship Club of the Harvard Business School, Nasdaq, Microsoft, and Coca-Cola. She has also appeared on more than 35 network television news shows including ABC, NBC, FOX, CW and more.

Dahryn Trivedi is a prodigious spiritual leader, young entrepreneur and inspiring speaker. Along with Guruji Mahendra Trivedi she devotes her time to expand and promote awareness about the power and potential of the Trivedi Effect®. She has shared her message at NASDAQ and has been featured on ABC, NBC, Fox, CW media in the United States.

Gopal Nayak is one the youngest enlightened spiritual gurus for the new generation in India. He is a pioneer in Biofield Energy Science. Nayak raises awareness about the potential impact of the Trivedi Effect for the beneficial transformation of all living organisms and non-living materials. Nayak is highly sought after by business leaders, politicians and celebrities throughout India and abroad. Nayak has transformed the lives of thousands of individuals from around the world, especially in the USA, Canada and Europe.

The Trivedi Effect® has been tested, measured, and validated in more than 6,000 scientific experiments globally, by world-renowned scientists and research institutes using the rigor of internationally accepted models of scientific research with the most sophisticated technologies available. Challenging the known frontiers of science, this research has resulted in over 500 publications in major international peer-reviewed scientific journals with more than 6,500 citations.

These publications are available in over 2,300 universities internationally including the prestigious Ivy League Universities, as well as the National Institutes of Health (NIH).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from stated results. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, “appear”, or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved.

Media Contacts

John K. Suzuki

(949) 445-3551

info@johnksuzuki.com

Alice Branton,

Chief Executive Officer

Trivedi Global, Inc.

(702) 907-8864

pr@trivedieffect.com

Xtalks Life Science Webinars

Speakers will also share lessons learned from translating English plain language summaries, discuss common pitfalls and recommendations to avoid them.

Toronto, Ontario (PRWEB)
November 18, 2019

Anyone who has been involved in the process of creating a plain language summary understands the challenges it entails. How do you take a detailed document and translate it into a plain language summary understandable by lay readers and experts? How do you establish a process to create summaries of the right quality, on time and reliably?

In this free webinar, expert speakers will explore how the pharmaceutical industry is engaging with patients and patient advocates to produce high-quality plain language summaries. This live session will be held on Friday, December 6, 2019 at 9am EST (2pm GMT/UK) and features the following speakers:

• 
      Debra Guerreiro, Associate Director, Plain Language Summary Program Lead, Janssen Data Transparency
•     Dianne Beland, Senior Manager, Clinical Trial Data Sharing/Disclosure, Celgene Corporation
•     Jessica Valencia, PhD, Operational Excellence Expert, Novartis Pharmaceuticals, Patient Engagement & Advocacy
•     Vidhi Vashisht, Associate Director, Clinical Trial Disclosure, Development Operations, Kinapse, a Syneos Health Company

Speakers will also share lessons learned from translating English plain language summaries, discuss common pitfalls and recommendations to avoid them.

At the end of this session, there will be an open question and answer session for the speakers to address any problems and challenges you face in plain language summary projects.

For more information or to register for this event, visit Writing Plain Language Summaries for Clinical Trials: What We Have Learned So Far.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Dr. Ajeet Kaushik has received the 2019 USERN Prize in biological sciences.

“The drugs we use now do not go only where they need to go, or sometimes they have side effects. We are treating one disease but creating other symptoms. I’m exploring nanotechnology that can carry a drug, selectively go to a place, and release the drug so we avoid using excessive drugs.”

LAKELAND, Fla. (PRWEB)
November 18, 2019

Dr. Ajeet Kaushik is determined to make detecting and treating diseases easy, accessible, and precise through the use of nanomaterials for biosensing and medicine.

His extensive work and resolute desire to improve the delivery of healthcare has earned Kaushik the prestigious Universal Scientific Education Research Network (USERN) Prize. He was named a laureate in the field of biological sciences during the group’s fourth annual congress on Nov. 8 in Budapest, Hungary.

USERN, a non-governmental, non-profit organization and network dedicated to non-military scientific advances, is committed to exploring science beyond international borders.

“I was speechless for a while,” said Kaushik, who is an assistant professor of chemistry at Florida Polytechnic University.

Kaushik did not attend the awards ceremony in person but did submit a video to be played at the event. He was among hundreds vying for the prize and one of five people who were recognized in different areas of study.

His submitted project, Nano-Bio-Technology for Personalized Health Care, focuses on using nanomaterials to create biosensors that will detect the markers of a disease at very low levels.

“Biosensing is not a new concept, but now we are making devices that are smarter and more capable,” Kaushik said.

He cited the recent zika virus epidemic that affected pregnant women and their fetuses, leading to significant health complications upon birth. “There was a demand to have a system that could detect the virus protein at a very low level, but there was no device. There was no diagnostic system,” he said.

Kaushik worked on the development of a smart zika sensor that could detect the disease at these low levels. “The kind of systems I’m focusing on can be customized in a way that we carry like a cell phone and do the tests wherever we need to do them,” he said.

In addition to using nanotechnology for the detection of diseases like zika, his research on nanoparticles is advancing efforts to precisely deliver medicine to a specific part of the body without affecting surrounding tissue or other parts of the body.

“The drugs we use now do not go only where they need to go, or sometimes they have side effects. We are treating one disease but creating other symptoms,” Kaushik said. “I’m exploring nanotechnology that can carry a drug, selectively go to a place, and release the drug so we avoid using excessive drugs.”

This nanomedicine could be used to precisely target brain tumors or other difficult-to-treat conditions. He has published papers in scientific journals about this work and also holds multiple patents.

“My whole approach is using smart material science for better health for everybody, which is accessible to everybody everywhere,” Kaushik said.

In addition to his USERN prize, Kaushik was named a USERN junior ambassador for 2020 and will work to advance the organization’s mission in the United States.

For the most recent university news, visit Florida Poly News.

About Florida Polytechnic University:

Florida Polytechnic University is accredited by the Southern Association of Colleges and Schools Commission on Colleges and is a member of the State University System of Florida. It is the only state university dedicated exclusively to STEM and offers ABET accredited degrees. Florida Poly is a powerful economic engine within the state of Florida, blending applied research with industry partnerships to give students an academically rigorous education with real-world relevance. Connect with Florida Poly online at http://www.floridapoly.edu.

Share article on social media or email:

Dr. Kawamoto

I believe in providing compassionate, quality care unique to each patient in a professional, fun and welcoming environment.

IRVINE, Calif. (PRWEB)
November 18, 2019

Smile Brands Inc., one of the nation’s leading providers of business support services to dental groups in the United States, today announced the grand opening of the first affiliated Aspire Dental office. This is the first office for the community of Irvine.

Patients will enjoy the convenient hours, comfortable office and full-service care at the new Aspire Dental office. This location provides full-service general dentistry, plus specialty care services, such as orthodontics (braces), Invisalign®, oral surgery, periodontics, endodontics, and implants. Located at 13234 Jamboree Road, in Irvine, the office will be open six days a week, including evenings and Saturdays. Aspire Dental accepts most major insurance plans and offers flexible financing options so patients can afford the care they need.

To celebrate the grand opening, the new Irvine dental office will offer a special $59 New Patient Check-Up Package, including an exam with oral cancer screening and digital x-rays, and Free Whitening for Life as long as patients maintain bi-annual teeth cleaning appointments.

Leading the clinical team in the new Aspire Dental office is Dr. Darcy S. Kawamoto. Dr. Kawamoto is an Irvine native with a passion for giving back. In addition to serving patients locally, Dr. Kawamoto has traveled to Nicaragua and Honduras on humanitarian mission trips to help local dentists provide care to the underserved.

“I believe in providing compassionate, quality care unique to each patient in a professional, fun and welcoming environment,” says Dr. Kawamoto. “I’m excited to partner with Smile Brands to open the first state-of-the-art Aspire Dental facility serving the community of Irvine.”

This new office is open on Mondays, Fridays and Saturdays from 8am – 5pm, Tuesdays and Thursdays from 9am – 6pm and Wednesdays from 10am – 7pm.

Prospective patients can call the new Irvine Aspire Dental office at 714-316-2966. People can also visit us online to schedule an appointment at the new Irvine location.

About Smile Brands Inc.

Based in Irvine California, Smile Brands Inc. is one of the largest providers of support services to dental groups in the United States. The culture-driven organization is the #1 ranked multi-location healthcare provider on Glassdoor’s 2019 Best Places to Work list. Smile Brands provides comprehensive business support services through exclusive long-term agreements with affiliate dental groups, so dentists can spend more time caring for their patients and less time on the administrative, marketing, and financial aspects of operating a dental practice. Smile Brands supports 440 Bright Now!® Dental, Monarch Dental®, Castle Dental®, A+ Dental Care, OneSmile Dental, Johnson Family Dental, P3 Dental Group, and DecisionOne Dental Partners offices in 18 states, including Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Maryland, Ohio, Oregon, Nevada, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington and Wisconsin. Smile Brands is a portfolio company of Gryphon Investors, a leading middle-market private equity firm based in San Francisco, CA. For more information, visit http://www.smilebrands.com.

Share article on social media or email:

We are very pleased that Dr. Wu has joined the MabPlex team. His extensive experience will play an important role in advancing MabPlex’s top-quality, global biopharmaceutical and biotechnology services while helping accelerate new drug development projects worldwide.

SAN DIEGO, Calif. and YANTAI, China (PRWEB)
November 18, 2019

MabPlex International, Ltd. (MabPlex), a leading, fully integrated, Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States, today announced the appointment of Yongjian Wu, Ph.D. as Chief Operating Officer (COO) of MabPlex USA.

Dr. Wu’s appointment will add to the overall strength of MabPlex offering a top quality service to global biopharmaceutical and biotechnology companies, while helping to accelerate new drug development projects worldwide.

“MabPlex offers one of the few globally integrated service platforms with high production capacity, something that is unique in our industry,” said Dr. Wu.

“The company employs a world-class professional team with diverse project experience in Asia and abroad. With robust technical and quality systems, large-capacity current Good Manufacturing Practice (cGMP) facilities, and a wealth of experience in successful project execution and Investigational New Drug application (IND) submissions, MabPlex truly provides a one-stop CDMO service for biologics, especially for antibody-drug conjugates (ADCs). I am honored and excited to join MabPlex and hope to contribute to the growth of the company while further enhancing our capabilities to serve the international market,” said Dr. Wu concluded.

Extensive experience

Dr. Wu has more than 18 years of global biopharmaceutical experience. Before joining MabPlex, Dr. Wu worked at Bayer, BioMarin, Genentech and Tanvex, with both internal manufacturing and quality organizations for the production of preclinical/clinical and commercial-ready materials, as well as with external Contract Research Organization (CRO) for preclinical, bioanalytical and clinical development of pipeline projects. He has advanced numerous new drug development projects from early research/preclinical stage to IND and Biologics License Applications (BLA), authoring regulatory filings and interacting with agencies during face to face meetings and inspections.

Dr. Wu obtained his Ph.D. in Immunology at the University of Toronto, Canada, with Professor Nobumichi Hozumi, MD, Ph,D. He did his postdoctoral training in the Department of Neurobiology at Stanford University, Stanford, California with Professor Eric Manvers Shooter MA, Sc.D., D.Sc., FRS.

About MabPlex

MabPlex International Ltd (MabPlex), a leading and fully integrated, global Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global (bio-) pharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. MabPlex currently has over 60,000 square meters of R&D and production facilities, a total of 9 monoclonal antibody (mAb) Drug Substance (DS) production lines, 2 Antibody-drug Conjugate (ADC) DS production lines, as well as mAb formulation and ADC formulation lines. The commercial production service is designed to help customers accelerate the progress of clinical trials and support market launch.

MabPlex has established a talented team of more than 400 employees provideding Contract Development and Manufacturing Organization (CDMO) services to more than 40 pharmaceutical companies around the world resulting in more than 12 Investigational New Drug application (IND) approvals with the United States Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and China’s National Medical Products Administration (NMPA). For more information, please visit our website at https://mabplexinc.com/

Share article on social media or email: